ES2734876T3 - Neprilisina como marcador pronóstico de insuficiencia cardiaca - Google Patents

Neprilisina como marcador pronóstico de insuficiencia cardiaca Download PDF

Info

Publication number
ES2734876T3
ES2734876T3 ES15750737T ES15750737T ES2734876T3 ES 2734876 T3 ES2734876 T3 ES 2734876T3 ES 15750737 T ES15750737 T ES 15750737T ES 15750737 T ES15750737 T ES 15750737T ES 2734876 T3 ES2734876 T3 ES 2734876T3
Authority
ES
Spain
Prior art keywords
nep
soluble
heart failure
vitro method
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15750737T
Other languages
English (en)
Spanish (es)
Inventor
Genis Antoni Bayes
Roses Josep Lupon
Ortega Amparo Galan
Martinez De Osaba Jaume Barallat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Original Assignee
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP filed Critical Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Application granted granted Critical
Publication of ES2734876T3 publication Critical patent/ES2734876T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96497—Enkephalinase (3.4.24.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
ES15750737T 2014-08-29 2015-08-14 Neprilisina como marcador pronóstico de insuficiencia cardiaca Active ES2734876T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14182846.7A EP2990800A1 (en) 2014-08-29 2014-08-29 Neprilysin as heartfailure (HF) prognostic marker
PCT/EP2015/068729 WO2016030209A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Publications (1)

Publication Number Publication Date
ES2734876T3 true ES2734876T3 (es) 2019-12-12

Family

ID=51421966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15750737T Active ES2734876T3 (es) 2014-08-29 2015-08-14 Neprilisina como marcador pronóstico de insuficiencia cardiaca

Country Status (11)

Country Link
US (1) US10203341B2 (enExample)
EP (2) EP2990800A1 (enExample)
JP (1) JP6661216B2 (enExample)
CN (1) CN107076758B (enExample)
AU (1) AU2015309112A1 (enExample)
CA (1) CA2959094A1 (enExample)
ES (1) ES2734876T3 (enExample)
MX (1) MX2017002453A (enExample)
RU (1) RU2017109086A (enExample)
SG (1) SG11201701393YA (enExample)
WO (1) WO2016030209A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4056585A4 (en) * 2019-11-06 2024-03-13 National University Corporation Kagawa University HEART FAILURE MARKER

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329648B (en) * 2001-09-03 2010-09-01 Intreat Pty Ltd Diagnosis and treatment of cancers and other conditions
US10324093B2 (en) * 2009-11-07 2019-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
CN103403554A (zh) * 2011-02-03 2013-11-20 雅培制药有限公司 慢性心力衰竭的预后和诊断方法
JP5945063B2 (ja) * 2012-04-12 2016-07-05 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性心不全が疑われる患者における有害事象の予後
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
US20140206632A1 (en) 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease
SI2956464T1 (en) * 2013-02-14 2018-08-31 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases)
CN105008337B (zh) * 2013-02-14 2017-08-04 诺华股份有限公司 具有改善的体内功效的作为nep抑制剂的取代的联苯基丁酸衍生物

Also Published As

Publication number Publication date
JP2017526924A (ja) 2017-09-14
JP6661216B2 (ja) 2020-03-11
RU2017109086A (ru) 2018-10-01
US10203341B2 (en) 2019-02-12
WO2016030209A1 (en) 2016-03-03
EP3186639B1 (en) 2019-03-20
SG11201701393YA (en) 2017-03-30
US20170254815A1 (en) 2017-09-07
CN107076758B (zh) 2019-10-22
MX2017002453A (es) 2017-10-23
AU2015309112A1 (en) 2017-04-06
EP2990800A1 (en) 2016-03-02
RU2017109086A3 (enExample) 2019-03-06
CN107076758A (zh) 2017-08-18
EP3186639A1 (en) 2017-07-05
CA2959094A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
US20240103018A1 (en) Galectin-3 immunoassay
CN105556308B (zh) 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
ES2841739T3 (es) Método para la determinación selectiva del factor de crecimiento placental 2
ES2913539T3 (es) Identificación de pacientes con fracción de acortamiento anómala
ES2558440T3 (es) Biomarcador para el diagnóstico, predicción y/o pronóstico de insuficiencia cardiaca aguda y usos del mismo
KR101996123B1 (ko) 특정 시기 내에 임신중독증의 개시를 배제하기 위한 sFlt-1/PlGF 또는 엔도글린/PlGF 비의 적용 수단 및 방법
CN103403554A (zh) 慢性心力衰竭的预后和诊断方法
JP2011523051A (ja) １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
JP2015092190A (ja) 生存率予測アッセイ
ES2824110T3 (es) Troponina como marcador de fibrilación auricular intermitente
ES2352351T3 (es) Métodos para la estratificación de la insuficiencia cardiaca.
ES2734876T3 (es) Neprilisina como marcador pronóstico de insuficiencia cardiaca
EP3311164B1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
JP2019514026A (ja) 一般集団におけるｌｖｈへの進行因子の同定のための可溶性ｓｔ２
WO2014009418A1 (en) TnT, NTproBNP, sFlt-1 for CURB65 IN PNEUMONIA
US20190250172A1 (en) Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress
HK1222454B (zh) 用於阑尾炎的诊断和预後及腹痛病因的区分的方法和组合物
WO2009150249A1 (en) Nt-probnp as prognostic indicator for the development of end stage renal disease in diabetes mellitus